Betalutin™ Successful Completion of Phase I Part of Phase I/II Study
|Monoclonal Antibody, Oncology, Trial Results, Phase I
|March 27, 2014
Nordic Nanovector AS announces today that its lead product candidate Betalutin™ has achieved the two major objectives from the phase I portion of the ongoing phase I/II clinical trial. The ongoing trial has demonstrated that Betalutin™ is safe and well tolerated in patients suffering from Non-Hodgkin Lymphoma and that the product has a clinically relevant effect in this patient population.
“We are pleased that the ongoing trial already has demonstrated that Betalutin™ is safe and well tolerated in patients suffering from Non-Hodgkin Lymphoma”
stated Jan A. Alfheim, CEO of Nordic Nanovector. “We are furthermore excited to note that the product candidate has shown a clinically relevant antitumor effect at all dose levels administered to date.”
The positive results from Phase I has enabled the company to establish the dose interval for the Phase II part of the clinical trial, which will assess the efficacy of Betalutin™ in patients suffering from relapsed Non-Hodgkin Lymphoma.
Betalutin™, is a pharmaceutical product candidate consisting of a radionuclide conjugated to a tumor seeking carrier/antibody, which can be used for irradiation of malignant metastasized tumors with minimal damage to nearby healthy normal tissue. This technology aims to prolong and improve the quality of lif